Racial disparities in treatment account for 20 percent of differences in BP control
Dec 17, 2021
Additionally, racial differences in visit attendance account for a smaller portion of differences in BP control.
Some U.S. adults with hypertension using meds that may raise BP
Dec 15, 2021
Overall, 15% of U.S. adults report using medications that may raise blood pressure, including 18.5% of adults with hypertension.
Increase in blood pressure observed during COVID-19 pandemic
Dec 06, 2021
Mean changes each month during the pandemic ranged from 1.10 to 2.50 mm Hg for systolic BP, 0.14 to 0.53 mm Hg for diastolic BP.
ASN: Chlorthalidone aids BP control in patients with CKD and HTN
Nov 12, 2021
For patients with stage 4 chronic kidney disease and poorly controlled hypertension, the addition of low dose of chlorthalidone improves blood pressure control.
Mobile tech program helps adults control high blood pressure
Oct 19, 2021
Greater engagement with self-management program was linked to lower systolic BP over time and lower risk for very high BP.
Use of antihypertensive drugs may increase risk for psoriasis
Oct 06, 2021
A meta-analysis shows that ACE inhibitors, ß-blockers, calcium-channel blockers and thiazide diuretics are associated with an increased risk for psoriasis.
Controlling hypertension in older adults: Up dose or add new med?
Oct 05, 2021
There was a bigger drop in systolic blood pressure, but less intensification sustainability was seen with addition of a new medication versus maximizing dose of the current drug.
Urinary stress hormone levels linked to incident hypertension
Sep 13, 2021
The risk for incident hypertension increased per doubling of norepinephrine, epinephrine, dopamine and cortisol during a median 6.5 years.
Monoclonal antibody therapy may cut COVID-19 hospitalizations
Aug 31, 2021
Lower hospitalization rates were seen at 14, 21 and 28 days for high-risk patients with mild-to-moderate COVID-19 who received casirivimab-imdevimab.
Ultra-low-dose combo cuts systolic BP in hypertension
Aug 30, 2021
The reduction in systolic blood pressure was greater at week 12 with the fixed-dose quadruple quarter-dose combo versus standard-dose monotherapy.